Literature DB >> 28342135

PACAP Protects Against Ethanol and Nicotine Toxicity in SH-SY5Y Cells: Implications for Drinking-Smoking Co-morbidity.

Sridharan Manavalan1,2, Bruk Getachew3, Kebreten F Manaye4, Syed J Khundmiri4, Antonei B Csoka5, Raechel McKinley5, Andrea Tamas2, Dora Reglodi2, Yousef Tizabi6.   

Abstract

The detrimental effects of heavy drinking and smoking are multiplied when the two are combined. Treatment modalities for each and especially for the combination are very limited. Although in low concentration, alcohol and nicotine, each may have beneficial effects including neuroprotection, their combination, instead of providing additive protection, may actually lead to toxicity in cell cultures. Pituitary adenylate cyclase-activating polypeptide (PACAP) is an endogenous 38 amino-acid peptide with demonstrated protection against neuronal injury, trauma as well as various endogenous and exogenous toxic agents. The aim of this study was to investigate whether PACAP may also protect against toxicity induced by high alcohol, high nicotine, or the combination of low alcohol and nicotine concentrations, and if so, whether this effect was mediated via PAC1 receptor. We used the neuroblastoma-derived SH-SY5Y cells and applied various colorimetric assays for determination of cell viability or toxicity. Results indicate that PACAP blocks toxicity induced by high alcohol and high nicotine as well as their combination at low concentrations. The effects of PACAP in turn were blocked by the PACAP antagonist (PACAP 6-38), indicating involvement of the PACAP receptor PAC1 and possibly vasoactive intestinal peptide (VIP) receptors in PACAP's protection. Moreover, no combined toxicity of low alcohol and low nicotine could be detected in calcium-free medium. These findings suggest possible beneficial effects of PACAP in preventing alcohol and nicotine toxicity and that calcium contributes to the damage induced by combination of low alcohol and nicotine in SH-SY5Y cells.

Entities:  

Keywords:  Alcohol; Calcium; Neuroprotection; Neurotoxicity; Nicotine; PACAP; SH-SY5Y cell line

Mesh:

Substances:

Year:  2017        PMID: 28342135     DOI: 10.1007/s12640-017-9727-8

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  36 in total

Review 1.  Brain reward circuitry: insights from unsensed incentives.

Authors:  Roy A Wise
Journal:  Neuron       Date:  2002-10-10       Impact factor: 17.173

Review 2.  Positive and negative effects of alcohol and nicotine and their interactions: a mechanistic review.

Authors:  Laura L Hurley; Robert E Taylor; Yousef Tizabi
Journal:  Neurotox Res       Date:  2011-09-20       Impact factor: 3.911

Review 3.  Moderate ethanol ingestion and cardiovascular protection: from epidemiologic associations to cellular mechanisms.

Authors:  Maike Krenz; Ronald J Korthuis
Journal:  J Mol Cell Cardiol       Date:  2011-10-23       Impact factor: 5.000

Review 4.  Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease and Drug-Induced Movement Disorders.

Authors:  Maryka Quik; Tanuja Bordia; Danhui Zhang; Xiomara A Perez
Journal:  Int Rev Neurobiol       Date:  2015-08-18       Impact factor: 3.230

5.  Protective effects of curcumin against rotenone and salsolinol-induced toxicity: implications for Parkinson's disease.

Authors:  Zakiya Qualls; Dwayne Brown; Carlana Ramlochansingh; Laura L Hurley; Yousef Tizabi
Journal:  Neurotox Res       Date:  2014-01       Impact factor: 3.911

6.  Binding sites for pituitary adenylate cyclase activating polypeptide (PACAP): comparison with vasoactive intestinal polypeptide (VIP) binding site localization in rat brain sections.

Authors:  Y Masuo; T Ohtaki; Y Masuda; M Tsuda; M Fujino
Journal:  Brain Res       Date:  1992-03-13       Impact factor: 3.252

7.  Antiapoptotic effects of nicotine in its protection against salsolinol-induced cytotoxicity.

Authors:  Robert L Copeland; Jharna R Das; Yasmine M Kanaan; Robert E Taylor; Yousef Tizabi
Journal:  Neurotox Res       Date:  2007-07       Impact factor: 3.911

8.  Tobacco exposure may enhance inflammation in prostate carcinoma patients: an explorative study in north Indian population.

Authors:  Shailendra Dwivedi; Apul Goel; Anil Mandhani; Sanjay Khattri; Kamlesh Kumar Pant
Journal:  Toxicol Int       Date:  2012-09

9.  Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis.

Authors:  V Bagnardi; M Rota; E Botteri; I Tramacere; F Islami; V Fedirko; L Scotti; M Jenab; F Turati; E Pasquali; C Pelucchi; C Galeone; R Bellocco; E Negri; G Corrao; P Boffetta; C La Vecchia
Journal:  Br J Cancer       Date:  2014-11-25       Impact factor: 7.640

10.  Pituitary adenylate cyclase-activating polypeptide (PACAP) has a neuroprotective function in dopamine-based neurodegeneration in rat and snail parkinsonian models.

Authors:  Gabor Maasz; Zita Zrinyi; Dora Reglodi; Dora Petrovics; Adam Rivnyak; Tibor Kiss; Adel Jungling; Andrea Tamas; Zsolt Pirger
Journal:  Dis Model Mech       Date:  2016-12-22       Impact factor: 5.758

View more
  10 in total

Review 1.  Low Vs. High Alcohol: Central Benefits Vs. Detriments.

Authors:  Yousef Tizabi; Bruk Getachew; Clifford L Ferguson; Antonei B Csoka; Karl M Thompson; Alejandra Gomez-Paz; Jana Ruda-Kucerova; Robert E Taylor
Journal:  Neurotox Res       Date:  2018-01-04       Impact factor: 3.911

2.  Chronic Nicotine Exposure Alters Metabotropic Glutamate Receptor 5: Longitudinal PET Study and Behavioural Assessment in Rats.

Authors:  Adrienne Müller Herde; Yoan Mihov; Stefanie D Krämer; Linjing Mu; Antoine Adamantidis; Simon M Ametamey; Gregor Hasler
Journal:  Neurotox Res       Date:  2019-05-22       Impact factor: 3.911

3.  Alteration of the PAC1 Receptor Expression in the Basal Ganglia of MPTP-Induced Parkinsonian Macaque Monkeys.

Authors:  M Feher; B Gaszner; A Tamas; A L Gil-Martinez; E Fernandez-Villalba; M T Herrero; D Reglodi
Journal:  Neurotox Res       Date:  2017-12-11       Impact factor: 3.911

4.  Butyrate Protects Against Salsolinol-Induced Toxicity in SH-SY5Y Cells: Implication for Parkinson's Disease.

Authors:  Bruk Getachew; Antonei B Csoka; Amna Bhatti; Robert L Copeland; Yousef Tizabi
Journal:  Neurotox Res       Date:  2020-06-22       Impact factor: 3.911

Review 5.  Effects of Pituitary Adenylate Cyclase Activating Polypeptide on Cell Death.

Authors:  Gabriella Horvath; Dora Reglodi; Eszter Fabian; Balazs Opper
Journal:  Int J Mol Sci       Date:  2022-04-29       Impact factor: 6.208

Review 6.  Pleiotropic pituitary adenylate cyclase-activating polypeptide (PACAP): Novel insights into the role of PACAP in eating and drug intake.

Authors:  Andrew T Gargiulo; Genevieve R Curtis; Jessica R Barson
Journal:  Brain Res       Date:  2019-12-26       Impact factor: 3.252

Review 7.  Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide (Part 2): biology and clinical importance in central nervous system and inflammatory disorders.

Authors:  Terry W Moody; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2021-04-01       Impact factor: 3.626

Review 8.  Review on PACAP-Induced Transcriptomic and Proteomic Changes in Neuronal Development and Repair.

Authors:  Adam Rivnyak; Peter Kiss; Andrea Tamas; Dorottya Balogh; Dora Reglodi
Journal:  Int J Mol Sci       Date:  2018-03-29       Impact factor: 5.923

Review 9.  Pituitary Adenylate Cyclase-Activating Polypeptide: A Promising Neuroprotective Peptide in Stroke.

Authors:  Yuanjian Fang; Reng Ren; Hui Shi; Lei Huang; Cameron Lenahan; Qin Lu; Lihui Tang; Yi Huang; Jiping Tang; Jianmin Zhang; John H Zhang
Journal:  Aging Dis       Date:  2020-12-01       Impact factor: 6.745

10.  Diabetes Affects the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)-Like Immunoreactive Enteric Neurons in the Porcine Digestive Tract.

Authors:  Katarzyna Palus; Michał Bulc; Jarosław Całka; Łukasz Zielonka; Marcin Nowicki
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.